Hohl Benjamin 4
4 · Enliven Therapeutics, Inc. · Filed Mar 10, 2026
Research Summary
AI-generated summary of this filing
Enliven Therapeutics (ELVN) CFO Benjamin Hohl Sells 10,000 Shares
What Happened
Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics (ELVN), sold 10,000 shares in an open-market transaction on March 6, 2026. The weighted-average sale price reported was $29.58 per share, resulting in total proceeds of approximately $295,839. This was a sale (disposition) rather than a purchase or grant.
Key Details
- Transaction date: March 6, 2026 (filed on March 10, 2026 — within the typical two-business-day Form 4 filing window).
- Reported price: weighted average $29.58; individual trades ranged from $29.43 to $29.7867 (see footnote F1).
- Shares sold: 10,000; total proceeds ≈ $295,839.
- Shares owned after transaction: not specified in the provided filing.
- Transaction type/code: Open-market sale (S).
- Footnotes: F1 notes multiple trades and availability of per-trade detail on request; F2 indicates some reported securities are restricted stock units (RSUs) that convert to shares subject to vesting conditions.
Context
Sales by executives can be routine (tax planning, diversification, liquidity) and do not by themselves indicate company performance. This filing documents a straightforward open-market sale; no exercise, gift, or 10b5-1 plan was stated in the provided notes.
Insider Transaction Report
Form 4
Hohl Benjamin
CHIEF FINANCIAL OFFICER
Transactions
- Sale
Common Stock
[F1][F2]2026-03-06$29.58/sh−10,000$295,839→ 51,000 total
Footnotes (2)
- [F1]This transaction was executed in multiple trades at prices ranging from $29.43 to $29.7867. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F2]Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
Signature
/s/ Benjamin Hohl|2026-03-10